CD4 and neoplasm: In vitro assays have demonstrated that CPX can trigger the release of type I IFN, enhancing the immunogenicity of tumor cells directly as well as improving anti-tumor immunity mediated by key immune cell types such as dendritic cells, CD4+ and CD8+ T cells, macrophages, and natural killer (NK) cells [25,26,27,28,29,30,31,32].